Woman has burning sensation in legs after vacation — then doctors find brain parasites
After a three-week-long vacation through Thailand, Japan and Hawaii, a 30-year-old woman learned she brought home an unwelcome souvenir, doctors said.
When the woman first returned home to the coast of New England, she felt fatigued and attributed it to jet lag from weeks of traveling, according to a Feb. 13 case report published in the New England Journal of Medicine.
Her lack of energy was accompanied by a slight burning sensation in her feet, according to the case report, and she took some ibuprofen to help alleviate the pain.
The medications were unsuccessful, and over the next eight days, the burning sensation spread up her body into her legs, doctors said.
The pain got worse when her legs were touched, according to the report, and she went to the emergency room.
Burning spreads to the chest
The woman went through a series of tests — she had a normal temperature, heart rate, blood pressure and blood oxygen saturation — and she was sent home with instructions to follow up with her primary care physician, doctors said.
But over the next three days, the burning feeling spread up to her chest and arms and she developed a headache that wouldn't wane even with over-the-counter pain medication, according to the report.
The woman went back to the emergency room, but again showed normal tests, so she was given intravenous pain medications that helped her still-pounding headache and was sent home with the same instructions, doctors said.
'After the patient arrived home from the emergency department, she took zolpidem ((a drug for insomnia) which had been prescribed for a family member) to help with sleep. On the day of the current presentation, confusion developed,' doctors said. 'In the morning when she awoke, she thought she needed to pack for vacation and was not redirectable when her roommate attempted to help her lie back down in bed. When confusion did not resolve after several hours, the patient's partner brought her to this hospital for further evaluation.'
Sushi, street food-filled vacation
Then, doctors learned more about her trip.
In Bangkok, Thailand, she toured the city and stopped for street food along the way, but said she didn't eat anything raw, according to the report. Her next stop was Tokyo, Japan, where she said she mainly stayed in the hotel, but ate sushi throughout her stay. The majority of her trip was spent in Hawaii swimming in the ocean and eating salads and sushi.
Her newly developed confusion led doctors to try new tests, including a lumbar puncture, a procedure that taps into the spine to test the cerebrospinal fluid, according to the report.
The fluid underwent a diagnostic test, and finally the woman had an answer — she had parasites in her brain.
Doctors discovered Angiostrongylus cantonensis, a parasitic species of roundworm also called rat lungworm.
An A. cantonensis infection can lead to human eosinophilic meningitis, which the woman was experiencing.
'Human infection, which was initially described in Taiwan, is now distributed across many tropical and subtropical regions in southeast Asia and the Pacific Islands (including Hawaii), with expanding distribution that now includes locally acquired infections in Europe, Australia, the southern United States and the Caribbean,' doctors said. 'Only five cases of angiostrongyliasis were confirmed in Hawaii in 2024; however, given that 9 to 10 million tourists visit Hawaii each year, many people may have been exposed to infection but may not have symptoms until after they leave Hawaii.'
The infection can come from a few sources: raw or undercooked snails or slugs, vegetables or fruit that have been contaminated by snails, slugs or flatworms or their slime, or by eating infected hosts like land crabs, freshwater prawns or frogs, doctors said.
It can take as many as 14 days after the parasites are ingested for symptoms to begin, according to the report.
Symptoms usually begin as headache, nausea, vomiting and fever, but then can spread to neurological symptoms after the parasite leaves the bloodstream, enters muscle, migrates to peripheral nerves and into the spinal column and brain, doctors said.
The woman was treated with a directed therapy of medications — albendazole, prednisone, gabapentin and amitriptyline — and her headache and burning sensation went away, doctors said. She was able to return home after six days in the hospital to recover.
The medical team includes Joseph Zunt, Amy K. Barczak and Daniel Y. Chang.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
14 hours ago
- Bloomberg
Lilly Obesity Pill to Rival Shots Holds Up to Scrutiny in Trial
Eli Lilly & Co. 's experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's competition with Novo Nordisk A/S. The highest dose helped patients with type 2 diabetes lose 7.6% of their body weight, during the 40-week study, according to data presented Saturday at the American Diabetes Association conference in Chicago. The results, published in the New England Journal of Medicine, found no signs of liver damage in patients on the drug, easing concerns that Lilly's medicine might run into side effects that derailed earlier attempts to develop potent weight-loss pills.
Yahoo
a day ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
Yahoo
11-06-2025
- Yahoo
What to know about Ozempic: Diabetes drug used off-label for weight loss sparks warnings
KUALA LUMPUR, June 11 — As global interest in weight loss remedies grows, the off-label use of diabetes medication Ozempic for shedding pounds in non-diabetic individuals has emerged as a trend. This rising popularity, fuelled by social media and anecdotal success stories, has prompted medical professionals to caution against its unsupervised use. Here's what you need to know about Ozempic, its side effects, and why expert supervision is essential before considering it for weight loss. What is Ozempic? Ozempic is a medication primarily approved for managing type 2 diabetes. Its active ingredient, semaglutide, mimics a hormone that targets areas of the brain involved in appetite regulation. Initially designed for diabetes treatment, Ozempic has gained popularity as a weight loss aid, even among non-diabetic individuals. Can Ozempic be used for weight loss? According to Universiti Teknologi MARA consultant endocrinologist Prof Dr Rohana Abdul Ghani, Ozempic is not intended for use as a weight loss medication for non-diabetic patients. 'Ozempic is approved in Malaysia specifically for managing type 2 diabetes. However, semaglutide's weight loss benefits have led some to seek it off-label for obesity treatment,' she said. For non-diabetic patients, semaglutide should be administered at a higher dose of 2.4mg weekly under another brand name, which is unavailable in Malaysia, she added. 'The off-label use of Ozempic among non-diabetic patients has led to a shortage for those with type 2 diabetes and reduced efficacy due to the lower dose,' said Dr Rohana. She also highlighted studies suggesting that regular use of weight loss drugs might establish a 'new normal' in the body, potentially leading to weight gain. One study in the New England Journal of Medicine found that low doses of semaglutide (between 0.25mg and 0.5mg) were linked to weight gain in some patients. What are the potential side effects? As with any medication, Ozempic comes with potential side effects. Dr Rohana said common gastrointestinal side effects include nausea, vomiting, constipation, or diarrhoea, which are typically self-limiting and subside within one to two weeks. She added that rare side effects include skin reactions at the injection site and worsening eyesight, particularly in patients with high blood sugar experiencing rapid improvement. 'Ozempic should not be used by patients with a history of thyroid cancer due to the rare risk of pancreatitis,' she said. Who shouldn't take Ozempic without medical advice? Dr Rohana stressed that no one should take Ozempic without consulting a doctor. 'Medications like Ozempic for obesity should be paired with proper diet and lifestyle changes. Without these, there's a risk of complications such as significant muscle mass loss or kidney issues from severe vomiting,' she said. 'These medications should only be prescribed by clinicians who are familiar with their effects and risks,' she added.
